Alkem Laboratories Q1 FY27: Profit down 21%, capex ₹75 cr

Key takeaway from Alkem’s June-quarter print

Alkem Laboratories reported its financial results for the quarter ended June 30, 2026 (Q1 FY27), showing steady top-line growth but a sharp year-on-year decline in profit. Consolidated revenue from operations rose 11% to ₹3,740 crore compared with ₹3,371 crore in the year-ago quarter. Consolidated net profit fell to ₹520 crore from ₹664 crore, a decline of about 21% year-on-year. Operating profit improved modestly, but margins narrowed versus last year. Alongside the results, the board approved a capacity addition at the company’s existing Baddi manufacturing facility in Himachal Pradesh.

What the company reported for Q1 FY27

For the April-June quarter, Alkem’s operating performance remained positive on an absolute basis. EBITDA increased 4% to ₹766 crore from ₹739 crore in Q1 FY26. EBITDA margin contracted to 20.48% from 21.92% in the corresponding quarter last year. The company also reported higher R&D spending in the quarter, which it quantified both in rupee terms and as a share of revenue. The results were approved by Alkem’s Board of Directors at a meeting held on August 14, 2026.

Profit decline despite revenue growth

The most notable feature of the quarter was the divergence between revenue growth and profit performance. While revenue from operations increased to ₹3,740 crore, consolidated net profit declined to ₹520 crore. The comparison base shows net profit of ₹664 crore in Q1 FY26, indicating a year-on-year fall of around 21% to 22% depending on rounding. In the same set of highlights, Alkem also disclosed tax expense of ₹251 crore versus ₹103 crore in the year-ago period. The quarter’s margin contraction suggests higher costs relative to revenue compared with the prior year.

India and international sales snapshot

Alkem’s sales mix showed growth across both domestic and overseas markets during the period. India sales rose 10.3% to ₹2,498 crore. International sales stood at ₹1,222 crore, increasing 16% year-on-year. These numbers indicate that both segments contributed to overall growth in revenue from operations. The company did not provide further geography-level splits in the provided details beyond the India versus international summary.

R&D spend rises in absolute terms

R&D expenditure increased in Q1 FY27, reflecting higher investment in development activities. The company reported R&D expenses of ₹150 crore, equal to 4% of total revenue from operations. In Q1 FY26, it spent ₹118 crore, which it said was 3.5% of total revenue from operations. The increase is visible both in rupee terms and as a percentage of revenue. Beyond these figures, no additional breakdown of R&D categories was provided in the available information.

Board clears new block at Baddi plant

Along with the earnings announcement, Alkem’s board approved setting up a new block within the existing manufacturing facility at Baddi, Himachal Pradesh. The company approved an investment of up to ₹75 crore for the project. The disclosure indicates an expansion within an existing site rather than a new greenfield facility. The company did not specify the product category, capacity, or commissioning timelines in the information provided.

Regulatory filing details and audit review

Alkem said its Board of Directors approved both standalone and consolidated unaudited financial results for the quarter ended June 30, 2026. It also reported that the board meeting commenced at 11:00 AM and concluded at 01:40 PM on August 14, 2026. The company’s auditors, Deloitte Haskins & Sells LLP, issued an unmodified review report on the interim financial results. For consolidated operations, the company disclosed basic and diluted EPS of ₹19.77 for the quarter.

Consolidated and standalone financial snapshot (as disclosed)

The company provided a set of consolidated and standalone figures in its results communication.

Market reaction and trading window update

Following the earnings, Alkem Laboratories shares were trading at ₹5,300 on the National Stock Exchange, down 2.74% at the time cited. The disclosure also mentioned that the trading window shall open on August 17, as per the company’s regulatory filing. Stock price movement around results often reflects how investors weigh revenue growth against profitability trends and margin movement. The company’s update on the Baddi capex plan added another data point for the market to assess near-term spending priorities.

Why this quarter matters for investors

The June-quarter numbers show Alkem growing revenue at a double-digit pace while facing pressure on reported profit and operating margin. The EBITDA increase to ₹766 crore indicates operating profitability improved in absolute terms, but margin contraction to 20.48% points to costs rising faster than revenue compared with the previous year. Higher R&D spend and a sharply higher tax expense figure were also part of the quarter’s disclosures. Separately, the board-approved capex of up to ₹75 crore at Baddi is a tangible investment decision that may influence future production capabilities, though timelines and output details were not provided.

Conclusion

Alkem Laboratories closed Q1 FY27 with revenue growth to ₹3,740 crore, EBITDA of ₹766 crore, and a year-on-year decline in consolidated net profit to ₹520 crore. The board also approved an investment of up to ₹75 crore for a new block at the Baddi facility. Investors will track further updates from the company on the Baddi project scope and any subsequent disclosures tied to operating margins, tax outgo, and R&D intensity. The next immediate corporate marker in the company’s communication is the reopening of the trading window on August 17.